References
- Vickers MR. The MRC long-term randomised control trial of hormone replacement therapy: background design and objectives. J Br Meno-pause Soc 1996;00:9–13
- Prentice RL, Rossouw JE, Johnson SR. The role of randomised controlled trials in assessing the benefits and risks of long term hormone replace-ment therapy: examples in the Women's Health Initiative. J Am Med Assoc 1996;3:71–6
- Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initia-tive Randomised Controlled Trial. J Am Med Assoc 2002;288:321–33
- Barrett-Connor E, Wenger NK, Grady D, et al. Hormone and non-hormone therapy for the maintenance of postmenopausal health: the need for randomised controlled trials of estrogen and raloxifene. J Women's Health 1998;7:839–47
- Blumenthal RS, Zacur H, Reis SE, Post WS. Beyond the null hypothesis — do the HERS results disprove the estrogen/coronary heart disease hypothesis? Am J Cardiol 2000;85:1015–17
- O'Connell D, Robertson J, Henry D, Gillespie W. A systematic review of the skeletal effects of estrogen therapy in postmenopausal women II. An assessment of treatment effects. Climacteric 1998;1:112–23
- Varas-Lorenzo C, Garcia-Rodriguez LA, Perez-Gutthann S, Duque-Oliart A. Hormone replace-ment therapy and incidence of acute myocardial infarction. A population based nested case control study. Circulation 2000;101:2572–8
- Hurley JS, Frost FJ, Trinkaus KM, Buatti MC, Emmett KE. Relationship of compliance with hormone replacement therapy to short-term healthcare utilization in a managed care popula-tion. Am J Managed Care 1998;4:1691–8
- Olsson H, Bladstrom A, Ingvar C, Moller TR. A population-based cohort study of HRT use and breast cancer in southern Sweden. Br J Cancer 2001;85:674–7
- Berman RS, Epstein RS, Lydick EG. Compliance of women in taking estrogen replacement therapy. J Women's Health 1996;5:213–20
- Ettinger B, Li DK, Klein R. Continuation of postmenopausal hormone replacement therapy:comparison of cyclic versus continuous com-bined schedules. Menopause 1996;3:185–9
- Stafford RS, Sag,lam D, Causino N, Blumenthal D. Low rates of hormone replace-ment in visits to United States primary care physi-cians. Am J Obstet Gynecol 1997;177:381–7
- MacLennan AH, Taylor AW, Wilson DH. Changes in the use of hormone replacement therapy in South Australia. Med J Aust 1995; 163:420–2
- MacLennan AH, Wilson DH, Taylor AW. Hormone replacement therapy in women at risk of cardiovascular disease in South Australia in 1997. Med J Aust 1999;170: 524–7
- MacLennan AH, Wilson DH, Taylor AW. Hormone replacement therapy — prevalence, compliance and the 'healthy women' notion. Climacteric 1998;1:42–9
- Wilson DH, Taylor AW, MacLennan AH. Health status of hormone replacement therapy users and non-users as determined by the SF-36 quality of life dimension. Climacteric 1998;1: 50–4
- Wilson DH, Wakefield M, Taylor AW. The South Australian Health Omnibus survey. Health Promotion J Aust 1992;2:47–9
- Centre for Population Studies in Epidemiology Brief Report, 2002–6. SA Health MonitorMethodology.www.health.sa.gov.au/pehs/cpse.html (Assessed 19/4/2002)
- Centre for Population Studies in Epidemiology Brief Report, 2002–4. SA Health OmnibusMethodology.www.health.sa.gov.au/pehs/cpse.html (Assessed 19/4/2002)
- Pitkin J. Compliance with estrogen replacement therapy: current issues. Climacteric 2002;5 (Suppl 2):12–19
- Moorhead T, Hannaford P, Warskyj M. Preva-lence and characteristics associated with use of hormone replacement therapy in Britain. Br J Obstet Gynaecol 1997;104:290–7
- MacLennan AH, Lester S, Moore V. Oral oestrogen replacement therapy versus placebo for hot flushes [Cochrane Review]. Cochrane Library, Issue 1,2001. Oxford: Update Software, 2001
- MacLennan AH, Wilson DH, Taylor AW. The escalating cost and prevalence of alternative medicine. Prey Med 2002;35:166–73